BPG is committed to discovery and dissemination of knowledge
Cited by in F6Publishing
For: Lim CX, Ricos MG, Dibbens LM, Heron SE. KCNT1 mutations in seizure disorders: the phenotypic spectrum and functional effects. J Med Genet 2016;53:217-25. [DOI: 10.1136/jmedgenet-2015-103508] [Cited by in Crossref: 55] [Cited by in F6Publishing: 50] [Article Influence: 9.2] [Reference Citation Analysis]
Number Citing Articles
1 Gertler TS, Cherian S, DeKeyser JM, Kearney JA, George AL Jr. KNa1.1 gain-of-function preferentially dampens excitability of murine parvalbumin-positive interneurons. Neurobiol Dis 2022;:105713. [PMID: 35346832 DOI: 10.1016/j.nbd.2022.105713] [Reference Citation Analysis]
2 Lin Z, Sang T, Yang Y, Wu Y, Dong Y, Ji T, Zhang Y, Wu Y, Gao K, Jiang Y. Efficacy of Anti-seizure Medications, Quinidine, and Ketogenic Diet Therapy for KCNT1-Related Epilepsy and Genotype-Efficacy Correlation Analysis. Front Neurol 2022;12:834971. [DOI: 10.3389/fneur.2021.834971] [Reference Citation Analysis]
3 Wan H, Wang X, Chen Y, Jiang B, Chen Y, Hu W, Zhang K, Shao X. Sleep-Related Hypermotor Epilepsy: Etiology, Electro-Clinical Features, and Therapeutic Strategies. Nat Sci Sleep 2021;13:2065-84. [PMID: 34803415 DOI: 10.2147/NSS.S330986] [Reference Citation Analysis]
4 Matt L, Pham T, Skrabak D, Hoffmann F, Eckert P, Yin J, Gisevius M, Ehinger R, Bausch A, Ueffing M, Boldt K, Ruth P, Lukowski R. The Na+-activated K+ channel Slack contributes to synaptic development and plasticity. Cell Mol Life Sci 2021;78:7569-87. [PMID: 34664085 DOI: 10.1007/s00018-021-03953-0] [Reference Citation Analysis]
5 Spoto G, Saia MC, Amore G, Gitto E, Loddo G, Mainieri G, Nicotera AG, Di Rosa G. Neonatal Seizures: An Overview of Genetic Causes and Treatment Options. Brain Sci 2021;11:1295. [PMID: 34679360 DOI: 10.3390/brainsci11101295] [Cited by in Crossref: 2] [Cited by in F6Publishing: 2] [Article Influence: 2.0] [Reference Citation Analysis]
6 Martinez LA, Lai YC, Holder JL Jr, Anderson AE. Genetics in Epilepsy. Neurol Clin 2021;39:743-77. [PMID: 34215385 DOI: 10.1016/j.ncl.2021.05.005] [Cited by in F6Publishing: 2] [Reference Citation Analysis]
7 de la Jara J, Vásquez-hernández C, Ramírez-rojo E, Moya-vilches J. Uncommon epileptic syndromes in children: a review. Seizure 2021;90:17-27. [DOI: 10.1016/j.seizure.2021.05.005] [Cited by in Crossref: 1] [Cited by in F6Publishing: 1] [Article Influence: 1.0] [Reference Citation Analysis]
8 Singh S, Agarwal P, Ravichandiran V. Two-Pore Domain Potassium Channel in Neurological Disorders. J Membr Biol 2021;254:367-80. [PMID: 34169340 DOI: 10.1007/s00232-021-00189-8] [Cited by in F6Publishing: 2] [Reference Citation Analysis]
9 Kravetz MC, Viola MS, Prenz J, Curi M, Bramuglia GF, Tenembaum S. Case Report of Novel Genetic Variant in KCNT1 Channel and Pharmacological Treatment With Quinidine. Precision Medicine in Refractory Epilepsy. Front Pharmacol 2021;12:648519. [PMID: 34122071 DOI: 10.3389/fphar.2021.648519] [Reference Citation Analysis]
10 Specchio N, Pietrafusa N, Perucca E, Cross JH. New paradigms for the treatment of pediatric monogenic epilepsies: Progressing toward precision medicine. Epilepsy Behav 2021;:107961. [PMID: 33867301 DOI: 10.1016/j.yebeh.2021.107961] [Cited by in Crossref: 1] [Cited by in F6Publishing: 1] [Article Influence: 1.0] [Reference Citation Analysis]
11 Griffin AM, Kahlig KM, Hatch RJ, Hughes ZA, Chapman ML, Antonio B, Marron BE, Wittmann M, Martinez-Botella G. Discovery of the First Orally Available, Selective KNa1.1 Inhibitor: In Vitro and In Vivo Activity of an Oxadiazole Series. ACS Med Chem Lett 2021;12:593-602. [PMID: 33859800 DOI: 10.1021/acsmedchemlett.0c00675] [Cited by in Crossref: 3] [Cited by in F6Publishing: 2] [Article Influence: 3.0] [Reference Citation Analysis]
12 Nikitin ES, Vinogradova LV. Potassium channels as prominent targets and tools for the treatment of epilepsy. Expert Opin Ther Targets 2021;25:223-35. [PMID: 33754930 DOI: 10.1080/14728222.2021.1908263] [Reference Citation Analysis]
13 Spitznagel BD, Mishra NM, Qunies AM, Prael FJ 3rd, Du Y, Kozek KA, Lazarenko RM, Denton JS, Emmitte KA, Weaver CD. VU0606170, a Selective Slack Channels Inhibitor, Decreases Calcium Oscillations in Cultured Cortical Neurons. ACS Chem Neurosci 2020;11:3658-71. [PMID: 33143429 DOI: 10.1021/acschemneuro.0c00583] [Cited by in Crossref: 5] [Cited by in F6Publishing: 4] [Article Influence: 2.5] [Reference Citation Analysis]
14 Nabbout R, Kuchenbuch M. Impact of predictive, preventive and precision medicine strategies in epilepsy. Nat Rev Neurol 2020;16:674-88. [PMID: 33077944 DOI: 10.1038/s41582-020-0409-4] [Cited by in Crossref: 10] [Cited by in F6Publishing: 17] [Article Influence: 5.0] [Reference Citation Analysis]
15 Kohli U, Ravishankar C, Nordli D. Cardiac phenotypic spectrum of KCNT1 mutations. Cardiol Young 2020;30:1935-9. [DOI: 10.1017/s1047951120002735] [Cited by in Crossref: 3] [Cited by in F6Publishing: 2] [Article Influence: 1.5] [Reference Citation Analysis]
16 Cole BA, Johnson RM, Dejakaisaya H, Pilati N, Fishwick CWG, Muench SP, Lippiat JD. Structure-Based Identification and Characterization of Inhibitors of the Epilepsy-Associated KNa1.1 (KCNT1) Potassium Channel. iScience 2020;23:101100. [PMID: 32408169 DOI: 10.1016/j.isci.2020.101100] [Cited by in Crossref: 5] [Cited by in F6Publishing: 7] [Article Influence: 2.5] [Reference Citation Analysis]
17 Niu LG, Liu P, Wang ZW, Chen B. Slo2 potassium channel function depends on RNA editing-regulated expression of a SCYL1 protein. Elife 2020;9:e53986. [PMID: 32314960 DOI: 10.7554/eLife.53986] [Cited by in Crossref: 2] [Cited by in F6Publishing: 3] [Article Influence: 1.0] [Reference Citation Analysis]
18 Helbig I, Ellis CA. Personalized medicine in genetic epilepsies - possibilities, challenges, and new frontiers. Neuropharmacology 2020;172:107970. [PMID: 32413583 DOI: 10.1016/j.neuropharm.2020.107970] [Cited by in Crossref: 11] [Cited by in F6Publishing: 19] [Article Influence: 5.5] [Reference Citation Analysis]
19 Bartolini E, Campostrini R, Kiferle L, Pradella S, Rosati E, Chinthapalli K, Palumbo P. Epilepsy and brain channelopathies from infancy to adulthood. Neurol Sci 2020;41:749-61. [PMID: 31838630 DOI: 10.1007/s10072-019-04190-x] [Cited by in Crossref: 3] [Cited by in F6Publishing: 12] [Article Influence: 1.0] [Reference Citation Analysis]
20 Ali SR, Malone TJ, Zhang Y, Prechova M, Kaczmarek LK. Phactr1 regulates Slack (KCNT1) channels via protein phosphatase 1 (PP1). FASEB J 2020;34:1591-601. [PMID: 31914597 DOI: 10.1096/fj.201902366R] [Cited by in Crossref: 4] [Cited by in F6Publishing: 6] [Article Influence: 1.3] [Reference Citation Analysis]
21 Licchetta L, Pippucci T, Baldassari S, Minardi R, Provini F, Mostacci B, Plazzi G, Tinuper P, Bisulli F; Collaborative Group of Italian League Against Epilepsy (LICE) Genetic Study Group on SHE. Sleep-related hypermotor epilepsy (SHE): Contribution of known genes in 103 patients. Seizure 2020;74:60-4. [PMID: 31835056 DOI: 10.1016/j.seizure.2019.11.009] [Cited by in Crossref: 8] [Cited by in F6Publishing: 15] [Article Influence: 2.7] [Reference Citation Analysis]
22 Alsaleem M, Carrion V, Weinstock A, Chandrasekharan P. Infantile refractory seizures due to de novo KCNT 1 mutation. BMJ Case Rep 2019;12:e231178. [PMID: 31653631 DOI: 10.1136/bcr-2019-231178] [Cited by in Crossref: 2] [Cited by in F6Publishing: 2] [Article Influence: 0.7] [Reference Citation Analysis]
23 Shi X, Chen J, Lu Q, He F, Zhou J, Zhou S, Zhou W, Wang M, Zou L. Whole-Exome Sequencing Revealing De Novo Heterozygous Variant OF KCNT1 in a Twin Discordant for Benign Epilepsy with Centrotemporal Spikes. J Paediatr Child Health 2018;54:709-10. [PMID: 29870100 DOI: 10.1111/jpc.13939] [Cited by in Crossref: 1] [Cited by in F6Publishing: 1] [Article Influence: 0.3] [Reference Citation Analysis]
24 El Kosseifi C, Cornet MC, Cilio MR. Neonatal Developmental and Epileptic Encephalopathies. Semin Pediatr Neurol 2019;32:100770. [PMID: 31813518 DOI: 10.1016/j.spen.2019.08.006] [Cited by in Crossref: 7] [Cited by in F6Publishing: 12] [Article Influence: 2.3] [Reference Citation Analysis]
25 Kuchenbuch M, Barcia G, Chemaly N, Carme E, Roubertie A, Gibaud M, Van Bogaert P, de Saint Martin A, Hirsch E, Dubois F, Sarret C, Nguyen The Tich S, Laroche C, des Portes V, Billette de Villemeur T, Barthez M, Auvin S, Bahi-buisson N, Desguerre I, Kaminska A, Benquet P, Nabbout R. KCNT1 epilepsy with migrating focal seizures shows a temporal sequence with poor outcome, high mortality and SUDEP. Brain 2019;142:2996-3008. [DOI: 10.1093/brain/awz240] [Cited by in Crossref: 14] [Cited by in F6Publishing: 19] [Article Influence: 4.7] [Reference Citation Analysis]
26 Gertler TS, Thompson CH, Vanoye CG, Millichap JJ, George AL Jr. Functional consequences of a KCNT1 variant associated with status dystonicus and early-onset infantile encephalopathy. Ann Clin Transl Neurol 2019;6:1606-15. [PMID: 31560846 DOI: 10.1002/acn3.50847] [Cited by in Crossref: 10] [Cited by in F6Publishing: 12] [Article Influence: 3.3] [Reference Citation Analysis]
27 Datta AN, Michoulas A, Guella I, Demos M; EPGEN Study. Two Patients With KCNT1-Related Epilepsy Responding to Phenobarbital and Potassium Bromide. J Child Neurol 2019;34:728-34. [DOI: 10.1177/0883073819854853] [Cited by in Crossref: 4] [Cited by in F6Publishing: 6] [Article Influence: 1.3] [Reference Citation Analysis]
28 Perucca P, Perucca E. Identifying mutations in epilepsy genes: Impact on treatment selection. Epilepsy Research 2019;152:18-30. [DOI: 10.1016/j.eplepsyres.2019.03.001] [Cited by in Crossref: 40] [Cited by in F6Publishing: 45] [Article Influence: 13.3] [Reference Citation Analysis]
29 Ko A, Kang H. Frequently Identified Genetic Developmental and Epileptic Encephalopathy: A Review Focusing on Precision Medicine. Ann Child Neurol 2019;27:2-12. [DOI: 10.26815/acn.2019.00066] [Cited by in Crossref: 3] [Cited by in F6Publishing: 1] [Article Influence: 1.0] [Reference Citation Analysis]
30 Dilena R, DiFrancesco JC, Soldovieri MV, Giacobbe A, Ambrosino P, Mosca I, Galli MA, Guez S, Fumagalli M, Miceli F, Cattaneo D, Darra F, Gennaro E, Zara F, Striano P, Castellotti B, Gellera C, Varesio C, Veggiotti P, Taglialatela M. Early Treatment with Quinidine in 2 Patients with Epilepsy of Infancy with Migrating Focal Seizures (EIMFS) Due to Gain-of-Function KCNT1 Mutations: Functional Studies, Clinical Responses, and Critical Issues for Personalized Therapy. Neurotherapeutics 2018;15:1112-26. [PMID: 30112700 DOI: 10.1007/s13311-018-0657-9] [Cited by in Crossref: 29] [Cited by in F6Publishing: 29] [Article Influence: 9.7] [Reference Citation Analysis]
31 Cataldi M, Nobili L, Zara F, Combi R, Prato G, Giacomini T, Capra V, De Marco P, Ferini-Strambi L, Mancardi MM. Migrating focal seizures in Autosomal Dominant Sleep-related Hypermotor Epilepsy with KCNT1 mutation. Seizure 2019;67:57-60. [PMID: 30903923 DOI: 10.1016/j.seizure.2019.02.019] [Cited by in Crossref: 7] [Cited by in F6Publishing: 4] [Article Influence: 2.3] [Reference Citation Analysis]
32 Kuchenbuch M, Benquet P, Kaminska A, Roubertie A, Carme E, de Saint Martin A, Hirsch E, Dubois F, Laroche C, Barcia G, Chemaly N, Milh M, Villeneuve N, Sauleau P, Modolo J, Wendling F, Nabbout R. Quantitative analysis and EEG markers of KCNT1 epilepsy of infancy with migrating focal seizures. Epilepsia 2019;60:20-32. [DOI: 10.1111/epi.14605] [Cited by in Crossref: 7] [Cited by in F6Publishing: 8] [Article Influence: 1.8] [Reference Citation Analysis]
33 Demarest ST, Brooks-kayal A. From molecules to medicines: the dawn of targeted therapies for genetic epilepsies. Nat Rev Neurol 2018;14:735-45. [DOI: 10.1038/s41582-018-0099-3] [Cited by in Crossref: 28] [Cited by in F6Publishing: 25] [Article Influence: 7.0] [Reference Citation Analysis]
34 Bausch AE, Ehinger R, Straubinger J, Zerfass P, Nann Y, Lukowski R. Loss of Sodium-Activated Potassium Channel Slack and FMRP Differentially Affect Social Behavior in Mice. Neuroscience 2018;384:361-74. [DOI: 10.1016/j.neuroscience.2018.05.040] [Cited by in Crossref: 5] [Cited by in F6Publishing: 4] [Article Influence: 1.3] [Reference Citation Analysis]
35 de Curtis M, Uva L, Gnatkovsky V, Librizzi L. Potassium dynamics and seizures: Why is potassium ictogenic? Epilepsy Research 2018;143:50-9. [DOI: 10.1016/j.eplepsyres.2018.04.005] [Cited by in Crossref: 17] [Cited by in F6Publishing: 18] [Article Influence: 4.3] [Reference Citation Analysis]
36 Gururaj S, Palmer EE, Sheehan GD, Kandula T, Macintosh R, Ying K, Morris P, Tao J, Dias KR, Zhu Y, Dinger ME, Cowley MJ, Kirk EP, Roscioli T, Sachdev R, Duffey ME, Bye A, Bhattacharjee A. A De Novo Mutation in the Sodium-Activated Potassium Channel KCNT2 Alters Ion Selectivity and Causes Epileptic Encephalopathy. Cell Rep 2017;21:926-33. [PMID: 29069600 DOI: 10.1016/j.celrep.2017.09.088] [Cited by in Crossref: 17] [Cited by in F6Publishing: 18] [Article Influence: 4.3] [Reference Citation Analysis]
37 Axeen EJ, Olson HE. Neonatal epilepsy genetics. Seminars in Fetal and Neonatal Medicine 2018;23:197-203. [DOI: 10.1016/j.siny.2018.01.003] [Cited by in Crossref: 19] [Cited by in F6Publishing: 19] [Article Influence: 4.8] [Reference Citation Analysis]
38 Cornet MC, Sands TT, Cilio MR. Neonatal epilepsies: Clinical management. Semin Fetal Neonatal Med 2018;23:204-12. [PMID: 29426806 DOI: 10.1016/j.siny.2018.01.004] [Cited by in Crossref: 21] [Cited by in F6Publishing: 24] [Article Influence: 5.3] [Reference Citation Analysis]
39 Zhang X, Wan JQ, Tong XP. Potassium channel dysfunction in neurons and astrocytes in Huntington's disease. CNS Neurosci Ther 2018;24:311-8. [PMID: 29377621 DOI: 10.1111/cns.12804] [Cited by in Crossref: 12] [Cited by in F6Publishing: 17] [Article Influence: 3.0] [Reference Citation Analysis]
40 Oyrer J, Maljevic S, Scheffer IE, Berkovic SF, Petrou S, Reid CA. Ion Channels in Genetic Epilepsy: From Genes and Mechanisms to Disease-Targeted Therapies. Pharmacol Rev 2018;70:142-73. [PMID: 29263209 DOI: 10.1124/pr.117.014456] [Cited by in Crossref: 92] [Cited by in F6Publishing: 98] [Article Influence: 23.0] [Reference Citation Analysis]
41 Meador KJ, Shin C. Pitfalls in developing precision medicine for genetic epilepsy. Neurology 2018;90:16-7. [PMID: 29196575 DOI: 10.1212/WNL.0000000000004774] [Cited by in Crossref: 3] [Cited by in F6Publishing: 3] [Article Influence: 0.6] [Reference Citation Analysis]
42 Kawasaki Y, Kuki I, Ehara E, Murakami Y, Okazaki S, Kawawaki H, Hara M, Watanabe Y, Kishimoto S, Suda K, Saitsu H, Matsumoto N. Three Cases of KCNT1 Mutations: Malignant Migrating Partial Seizures in Infancy with Massive Systemic to Pulmonary Collateral Arteries. The Journal of Pediatrics 2017;191:270-4. [DOI: 10.1016/j.jpeds.2017.08.057] [Cited by in Crossref: 17] [Cited by in F6Publishing: 14] [Article Influence: 3.4] [Reference Citation Analysis]
43 McTague A, Nair U, Malhotra S, Meyer E, Trump N, Gazina EV, Papandreou A, Ngoh A, Ackermann S, Ambegaonkar G, Appleton R, Desurkar A, Eltze C, Kneen R, Kumar AV, Lascelles K, Montgomery T, Ramesh V, Samanta R, Scott RH, Tan J, Whitehouse W, Poduri A, Scheffer IE, Chong WKK, Cross JH, Topf M, Petrou S, Kurian MA. Clinical and molecular characterization of KCNT1-related severe early-onset epilepsy. Neurology 2018;90:e55-66. [PMID: 29196579 DOI: 10.1212/WNL.0000000000004762] [Cited by in Crossref: 47] [Cited by in F6Publishing: 46] [Article Influence: 9.4] [Reference Citation Analysis]
44 Saito T, Ishii A, Sugai K, Sasaki M, Hirose S. A de novo missense mutation in SLC12A5 found in a compound heterozygote patient with epilepsy of infancy with migrating focal seizures: SAITO et al . Clin Genet 2017;92:654-8. [DOI: 10.1111/cge.13049] [Cited by in Crossref: 23] [Cited by in F6Publishing: 20] [Article Influence: 4.6] [Reference Citation Analysis]
45 Maljevic S, Reid CA, Petrou S. Models for discovery of targeted therapy in genetic epileptic encephalopathies. J Neurochem 2017;143:30-48. [PMID: 28742937 DOI: 10.1111/jnc.14134] [Cited by in Crossref: 21] [Cited by in F6Publishing: 24] [Article Influence: 4.2] [Reference Citation Analysis]
46 Noebels J. Precision physiology and rescue of brain ion channel disorders. J Gen Physiol 2017;149:533-46. [PMID: 28428202 DOI: 10.1085/jgp.201711759] [Cited by in Crossref: 18] [Cited by in F6Publishing: 14] [Article Influence: 3.6] [Reference Citation Analysis]
47 Hansen N, Widman G, Hattingen E, Elger CE, Kunz WS. Mesial temporal lobe epilepsy associated with KCNT1 mutation. Seizure 2017;45:181-3. [PMID: 28081520 DOI: 10.1016/j.seizure.2016.12.018] [Cited by in Crossref: 10] [Cited by in F6Publishing: 11] [Article Influence: 1.7] [Reference Citation Analysis]
48 Dos Passos GR, Fernández AC, Vasques AM, Martins WA, Palmini A. Mother and daughter with adolescent-onset severe frontal lobe dysfunction and epilepsy. Dement Neuropsychol 2016;10:238-43. [PMID: 29213461 DOI: 10.1590/S1980-5764-2016DN1003011] [Reference Citation Analysis]
49 Hani AJ, Mikati MA. Current and Emerging Therapies of Severe Epileptic Encephalopathies. Semin Pediatr Neurol 2016;23:180-6. [PMID: 27544475 DOI: 10.1016/j.spen.2016.06.001] [Cited by in Crossref: 8] [Cited by in F6Publishing: 7] [Article Influence: 1.3] [Reference Citation Analysis]
50 Imbrici P, Liantonio A, Camerino GM, De Bellis M, Camerino C, Mele A, Giustino A, Pierno S, De Luca A, Tricarico D, Desaphy JF, Conte D. Therapeutic Approaches to Genetic Ion Channelopathies and Perspectives in Drug Discovery. Front Pharmacol 2016;7:121. [PMID: 27242528 DOI: 10.3389/fphar.2016.00121] [Cited by in Crossref: 70] [Cited by in F6Publishing: 66] [Article Influence: 11.7] [Reference Citation Analysis]